A Phase I Trial and Pharmacokinetic Study of Sorafenib in Children with Refractory Solid Tumors or Leukemias: A Children’s Oncology Group Phase I Consortium Report

PURPOSE: To determine the dose-limiting toxicities (DLT), maximum tolerated dose (MTD), pharmacokinetics, and pharmacodynamics of sorafenib in children with refractory extracranial solid tumors and evaluate the tolerability of the solid tumor MTD in children with refractory leukemias. EXPERIMENTAL D...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Widemann, Brigitte C., Kim, AeRang, Fox, Elizabeth, Baruchel, Sylvain, Adamson, Peter C., Ingle, Ashish M., Bender, Julia Glade, Burke, Michael, Weigel, Brenda, Stempak, Diana, Balis, Frank M., Blaney, Susan M.
Formato: Artigo
Lenguaje:Inglês
Publicado: 2012
Materias:
Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC4008314/
https://ncbi.nlm.nih.gov/pubmed/22962440
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-11-3284
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares